This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Alexion Pharmaceuticals, Inc.
Drug Names(s): MP4
Description: MP4 is a recombinant fusion protein that mimics two components of myelin, the fatty nerve sheath damaged in multiple sclerosis patients. MP4 is a fusion of portions of myelin basic protein and proteolipid protein.
In theory, MP4 acts by inducing apoptosis (programmed cell death) in T cells that specifically recognize these myelin components and cause the destruction seen in multiple sclerosis patients. Alexion calls MP4 an “apogen,” or apoptosis-inducing antigen.
Preclinical studies show that MP4 has the potential to reduce the destruction of myelin by T cells. Clinical studies have been planned, and the FDA has accepted the MP4 IND. However, initiation of phase I studies has been on hold for five years as Alexion has attempted to find a partner to fund these trials.
Deal Structure: Alexion has been looking for a partner to develop MP4 for five years.
Pink Sheet New EU Approvals
Additional information available to subscribers only: